Here is a number worth sitting with: in a study of 125,474 US adults published in JAMA Network Open, 53.6% of people who started a GLP-1 for weight had stopped within one year. By two years, 72.2% had stopped. Discontinuing isn't the exception on these medications. It's the norm.
And most of it isn't by choice. When Cleveland Clinic researchers looked at around 8,000 real-world patients in 2026, the top reason for stopping wasn't side effects or reaching a goal. It was cost and insurance coverage. Several state Medicaid programs ended GLP-1 weight coverage in 2025 and 2026, and some employer plans now cap coverage at two years. Which means thousands of people are having their last covered month right now, often with barely any warning.
“Going right off like that, it's easier said than done.”
— Kyra Wensley, 25, told KFF Health News after losing coverage
What the research actually says about stopping
Two honest facts, side by side. First, the trial data: when people in the semaglutide STEP-1 extension stopped abruptly, they regained roughly two thirds of the weight they'd lost within a year. A University of Cambridge meta-analysis found a similar pattern, with regain leveling off so that about a quarter of the loss was kept.
Second, the real-world data, which is gentler: Cleveland Clinic's 2026 study found that patients with obesity who stopped regained an average of only 0.5% of body weight at one year, and 45% maintained or kept losing. Why the gap? Real patients don't stop the way trials force them to. In that study, 27% switched to a different medication, 20% restarted the original one, and 14% moved to clinician-supervised lifestyle work.
“Many patients do not give up on their obesity treatment journey, even if they need to stop their initial medication.”
— Dr. Hamlet Gasoyan, Cleveland Clinic study author
Read those together and the lesson isn't “stopping ruins everything.” It's that the people who do well after stopping are the ones who stop with a plan, made with a clinician, instead of just running out.
The guidance gap nobody tells you about
Here's the uncomfortable part: there is no standardized, trial-tested protocol for tapering off a GLP-1 or for finding a “maintenance dose.” The trials studied starting and continuing, not landing. A dedicated maintenance trial (SURMOUNT-MAINTAIN) is underway but hasn't reported. Microdosing and dose-stretching circulate in forums, but no professional body endorses them and no trial has tested them.
That gap is exactly why this can't be a decision you make alone from Reddit threads. What happens at your exit is a clinical judgment call, and judgment calls go better when your clinician has your full picture: your dose history, your trend, what happened at each level.
The questions to bring to the stopping conversation
- Given my history, would you taper me down or stop directly, and why?
- What should we watch in the first three months, and how often should I weigh in?
- At what point of regain would you want to see me again?
- If I want to restart later, what does that look like? Would I re-titrate from the lowest dose?
- If cost is the reason I'm stopping, are there options we haven't tried, like manufacturer direct programs or a different covered medication?
- What support exists after the medication: nutrition, strength training, follow-up cadence?
Bring your dose timeline and weight trend on one page. The stopping conversation is a planning meeting, and your history is the agenda. The free Appointment Prep Kit includes the one-page template plus a question set for reducing or stopping.
Quick answers
Will I gain the weight back if I stop a GLP-1?
Trial data shows substantial regain after abrupt stopping (roughly two thirds of lost weight within a year in the STEP-1 extension). Real-world data is milder: many patients switch medications, restart, or maintain with clinical support. What happens depends heavily on the exit plan you make with your provider.
Do you have to take Wegovy or Zepbound forever?
Not necessarily, but there is no standardized off-ramp protocol yet. Whether to continue, taper, switch, or stop is an individual clinical decision. Bring your dose history and goals to your provider and plan the exit rather than letting a refill lapse decide it.
Can I stop and restart a GLP-1 later?
Many people do. In Cleveland Clinic's 2026 real-world study, 20% of patients who stopped restarted the same medication. Restarting often means re-titrating, so ask your provider what a restart would look like before you stop.
Is there an approved maintenance dose or microdosing schedule?
No. Maintenance dosing and microdosing have not been established in clinical trials, and no professional body endorses a specific protocol. If you're considering a lower dose, that's a conversation for your prescriber, not a forum.